SITE003-0121

SITE003 (CAN) › SITE003-0121

SITE003-0121

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2026-01-24

enrolled

AEs

5

Serious

0

Dropout signal

–

Adverse events

5

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-02-17 (study day 198); relationship: not assessed

moderate assessed

Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-11-23 (study day 112); relationship: not assessed

mild assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-11-18 (study day 107); relationship: NOT RELATED

mild assessed

Grade 2 Constipation — outcome: UNKNOWN; onset 2022-11-06 (study day 95); relationship: not assessed

moderate assessed

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-10-23 (study day 81); relationship: NOT RELATED

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.